Write in a clean editor, then format for European Heart Journal - Cardiovascular Pharmacotherapy in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
European Heart Journal - Cardiovascular Pharmacotherapy is a peer-reviewed journal published by Oxford University Press, covering Atrial Fibrillation Management and Outcomes, Antiplatelet Therapy and Cardiovascular Diseases, Acute Myocardial Infarction Research.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', European Heart Journal - Cardiovascular Pharmacotherapy, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — European Heart Journal - Cardiovascular Pharmacotherapy has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Atrial Fibrillation Management and Outcomes Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Heart Failure Treatment and Management Lipoproteins and Cardiovascular Health |
| ISSN | 2055-6837 |
| Citation impact (2-yr) | 4.66 |
| h-index | 59 |
| i10-index | 405 |
| Total citations | 15,963 |
| Article processing charge | $3,895 |
| Top institutions publishing here | Karolinska Institutet |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so…
Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type of acute organ damage is the principal determinant of: (i) the drug of choice, (ii) the target BP, and (iii) the timeframe in which BP should be…
Proprotein convertase subtilisin/kexin Type 9 (PCSK9) is now identified as an important and major player in hypercholesterolaemia and atherosclerosis pathophysiology. PCSK9, through promoting lysosomal degradation of hepatic low-density lipoprotein (LDL) receptor, can decrease the clearance of plasma LDLs, leading to hypercholesterolaemia and consequent atherosclerotic plaque formation. Hypercholesterolaemia has been found to promote systemic and vascular…
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events…
